StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Palvella Therapeutics cash

Cash and short-term investments held at the end of each period.

Palvella Therapeutics's cash was $250.60M at Jun 30, 2026. For fiscal 2025 it was $57.98M, down 30.6% from the year before. Over ten years it grew 7.0% a year on average. The highest annual figure on record is $128.11M in fiscal 2018.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$57.98M-30.6%
FY2024Dec 31, 2024$83.60M+216.7%
FY2023Dec 31, 2023$26.40M-55.4%
FY2022Dec 31, 2022$59.20M-49.7%
FY2021Dec 31, 2021$117.76M+67.2%
FY2020Dec 31, 2020$70.44M-32.4%
FY2019Dec 31, 2019$104.15M-18.7%
FY2018Dec 31, 2018$128.11M+76.4%
FY2017Dec 31, 2017$72.63M+147.4%
FY2016Dec 31, 2016$29.36M+0.0%
FY2015Dec 31, 2015$29.35M+58.9%
FY2014Dec 31, 2014$18.47M+400.7%
FY2013Dec 31, 2013$3.69M-41.7%
FY2012Dec 31, 2012$6.33M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$250.60M+255.8%
Q1 FY2026Mar 31, 2026$261.85M+246.2%
Q4 FY2025Dec 31, 2025$57.98M-30.6%
Q3 FY2025Sep 30, 2025$63.57M+227.7%
Q2 FY2025Jun 30, 2025$70.43M+257.5%
Q1 FY2025Mar 31, 2025$75.63M+295.9%
Q4 FY2024Dec 31, 2024$83.60M+216.7%
Q3 FY2024Sep 30, 2024$19.40M-56.7%
Q2 FY2024Jun 30, 2024$19.70M-64.1%
Q1 FY2024Mar 31, 2024$19.10M-60.5%
Q4 FY2023Dec 31, 2023$26.40M-55.4%
Q3 FY2023Sep 30, 2023$44.80M-35.8%
Q2 FY2023Jun 30, 2023$54.90M-32.1%
Q1 FY2023Mar 31, 2023$48.40M-51.7%
Q4 FY2022Dec 31, 2022$59.20M-49.7%
Q3 FY2022Sep 30, 2022$69.80M-44.2%
Q2 FY2022Jun 30, 2022$80.90M-32.1%
Q1 FY2022Mar 31, 2022$100.30M+50.1%
Q4 FY2021Dec 31, 2021$117.76M+67.2%
Q3 FY2021Sep 30, 2021$125.10M+51.5%
Q2 FY2021Jun 30, 2021$119.10M+54.3%
Q1 FY2021Mar 31, 2021$66.80M-23.0%
Q4 FY2020Dec 31, 2020$70.44M-32.4%
Q3 FY2020Sep 30, 2020$82.60M-4.2%
Q2 FY2020Jun 30, 2020$77.20M-22.6%
Q1 FY2020Mar 31, 2020$86.80M-21.7%
Q4 FY2019Dec 31, 2019$104.15M-18.7%
Q3 FY2019Sep 30, 2019$86.20M-37.2%
Q2 FY2019Jun 30, 2019$99.70M-34.0%
Q1 FY2019Mar 31, 2019$110.80M-30.6%
Q4 FY2018Dec 31, 2018$128.11M+76.4%
Q3 FY2018Sep 30, 2018$137.30M+52.7%
Q2 FY2018Jun 30, 2018$150.98M+200.0%
Q1 FY2018Mar 31, 2018$159.58M+188.9%
Q4 FY2017Dec 31, 2017$72.63M+147.4%
Q3 FY2017Sep 30, 2017$89.92M+146.0%
Q2 FY2017Jun 30, 2017$50.32M–
Q1 FY2017Mar 31, 2017$55.24M–
Q4 FY2016Dec 31, 2016$29.36M–
Q3 FY2016Sep 30, 2016$36.56M–

More Palvella Therapeutics figures

See a number that looks wrong?